Loading
Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL.
Elias Jabbour led the MD Anderson regimens combining low-intensity chemotherapy with inotuzumab ozogamicin and blinatumomab in older adults with ALL, and the chemotherapy-free ponatinib plus blinatumomab regimen for Philadelphia-positive ALL, which produce complete molecular remissions in most patients and challenge the need for transplant. He was senior author of INO-VATE and leads adult ALL research at MD Anderson.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific) and the tags all, immunotherapy.
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Blinatumomab, MD Anderson Cancer Center.
Shares Blinatumomab, CD19, T-cell engagers (bispecific), Acute lymphoblastic leukaemia and the tag all.
Shares Blinatumomab, CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, CD3, CD19, Acute lymphoblastic leukaemia.
Shares Blinatumomab, T-cell engagers (bispecific), Acute lymphoblastic leukaemia.
Shares CD3, CD19, T-cell engagers (bispecific).
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag all.